# EDWARDS LIFESCIENCES CORPORATION (EW) FY2026 Q2 P&L / Income Statement

- Company: EDWARDS LIFESCIENCES CORPORATION (EW)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0001099800-26-000043
- Page: https://plicit.ai/financials/ew/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/ew-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,741,000,000 US dollars
- **Cost of sales**: 392,400,000 US dollars
- **Gross profit**: 1,348,600,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 835,400,000 US dollars
- **Operating income, net**: 513,200,000 US dollars
- **Other income (expense), net (calculated)**: 6,600,000 US dollars
- **Income from continuing operations before provision for income taxes**: 519,800,000 US dollars
- **Provision for income taxes**: 278,400,000 US dollars
- **Net income**: 241,400,000 US dollars
- **Transcatheter Aortic Valve Replacement**: 1,258,300,000 US dollars
- **Transcatheter Mitral and Tricuspid Therapies**: 198,600,000 US dollars
- **Surgical**: 284,100,000 US dollars
- **Selling, general, and administrative expenses**: 561,200,000 US dollars
- **Research and development expenses**: 278,900,000 US dollars
- **Certain litigation expenses**: 6,300,000 US dollars
- **Separation costs**: 0 US dollars
- **Other operating income**: negative 11,000,000 US dollars
- **Loss from discontinued operations, net of tax**: 0 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
- Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $241.90 M; to noncontrolling interests: −$500.00 K.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/ew/fy2026-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/ew-fy2026-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,741,000,000 US dollars
- **Cost of sales**: 392,400,000 US dollars
- **Gross profit**: 1,348,600,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 835,400,000 US dollars
- **Operating income, net**: 513,200,000 US dollars
- **Other income (expense), net (calculated)**: 6,600,000 US dollars
- **Income from continuing operations before provision for income taxes**: 519,800,000 US dollars
- **Provision for income taxes**: 278,400,000 US dollars
- **Net income**: 241,400,000 US dollars
- **United States**: 1,003,500,000 US dollars
- **Europe**: 439,600,000 US dollars
- **Japan**: 96,400,000 US dollars
- **Rest of World**: 201,500,000 US dollars
- **Selling, general, and administrative expenses**: 561,200,000 US dollars
- **Research and development expenses**: 278,900,000 US dollars
- **Certain litigation expenses**: 6,300,000 US dollars
- **Separation costs**: 0 US dollars
- **Other operating income**: negative 11,000,000 US dollars
- **Loss from discontinued operations, net of tax**: 0 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
- Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $241.90 M; to noncontrolling interests: −$500.00 K.